JP2017518360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518360A5 JP2017518360A5 JP2017505735A JP2017505735A JP2017518360A5 JP 2017518360 A5 JP2017518360 A5 JP 2017518360A5 JP 2017505735 A JP2017505735 A JP 2017505735A JP 2017505735 A JP2017505735 A JP 2017505735A JP 2017518360 A5 JP2017518360 A5 JP 2017518360A5
- Authority
- JP
- Japan
- Prior art keywords
- substituents
- heterocyclic group
- membered
- optionally
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 39
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 7
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 206010029113 Neovascularisation Diseases 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 231100000673 dose–response relationship Toxicity 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 230000003018 neuroregenerative effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1406956.1A GB201406956D0 (en) | 2014-04-17 | 2014-04-17 | Compounds |
| GB1406956.1 | 2014-04-17 | ||
| PCT/GB2015/051172 WO2015159103A1 (en) | 2014-04-17 | 2015-04-17 | Piperazine derivatives for treating disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518360A JP2017518360A (ja) | 2017-07-06 |
| JP2017518360A5 true JP2017518360A5 (enExample) | 2018-06-07 |
| JP6579714B2 JP6579714B2 (ja) | 2019-09-25 |
Family
ID=50928932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505735A Active JP6579714B2 (ja) | 2014-04-17 | 2015-04-17 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9695160B2 (enExample) |
| EP (1) | EP3131886B1 (enExample) |
| JP (1) | JP6579714B2 (enExample) |
| CN (1) | CN107001344B (enExample) |
| AU (1) | AU2015248656B2 (enExample) |
| ES (1) | ES2836105T3 (enExample) |
| GB (1) | GB201406956D0 (enExample) |
| WO (1) | WO2015159103A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2908811B1 (en) * | 2012-10-17 | 2020-12-09 | Exonate Limited | Compounds useful for treating ocular neovascularisation |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| CA3054945A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
| CN111448193B (zh) | 2017-09-27 | 2023-12-22 | 埃克森纳特有限公司 | Srpk1抑制剂 |
| CN108912116A (zh) * | 2018-08-15 | 2018-11-30 | 翟学旭 | 一种含氮杂环类衍生物及其在视网膜疾病中的应用 |
| EP4093734A1 (en) * | 2020-01-22 | 2022-11-30 | F. Hoffmann-La Roche AG | Novel heterocyclic compounds |
| GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| JP2024525793A (ja) | 2021-07-15 | 2024-07-12 | エフ． ホフマン－ラ ロシュ アーゲー | イミダゾール誘導体及びその抗生物質としての使用 |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
| CN116898971B (zh) * | 2023-07-17 | 2024-11-22 | 武汉大学人民医院（湖北省人民医院） | Srpk3基因在制备治疗心肌肥厚的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2840314B1 (fr) | 2002-06-03 | 2004-08-20 | Inst Francais Du Petrole | Methode d'isolation thermique, procede de preparation d'un gel isolant et gel isolant obtenu |
| DK2666481T3 (en) * | 2003-12-26 | 2019-02-25 | Masatoshi Hagiwara | A method for regulating the phosphorylation of SR protein and antiviral agents comprising an SR protein activity regulator as the active ingredient |
| MX2009004786A (es) * | 2006-10-31 | 2009-06-05 | Schering Corp | Derivados de anilinopiperazina y sus metodos de uso. |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| EP2358382A2 (en) | 2008-11-22 | 2011-08-24 | The University of Bristol | NOVEL USES OF VEGFxxxB |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| EP2908811B1 (en) * | 2012-10-17 | 2020-12-09 | Exonate Limited | Compounds useful for treating ocular neovascularisation |
-
2014
- 2014-04-17 GB GBGB1406956.1A patent/GB201406956D0/en not_active Ceased
-
2015
- 2015-04-17 JP JP2017505735A patent/JP6579714B2/ja active Active
- 2015-04-17 WO PCT/GB2015/051172 patent/WO2015159103A1/en not_active Ceased
- 2015-04-17 EP EP15718262.7A patent/EP3131886B1/en active Active
- 2015-04-17 US US15/304,678 patent/US9695160B2/en active Active
- 2015-04-17 CN CN201580031650.5A patent/CN107001344B/zh active Active
- 2015-04-17 AU AU2015248656A patent/AU2015248656B2/en active Active
- 2015-04-17 ES ES15718262T patent/ES2836105T3/es active Active
-
2017
- 2017-05-31 US US15/609,596 patent/US9796707B2/en active Active
- 2017-09-19 US US15/708,315 patent/US9932330B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2021002428A (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2013512903A5 (enExample) | ||
| NZ708593A (en) | Novel pyrazole derivative | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| JP2017527532A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| JP2015511609A5 (enExample) | ||
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| JP2019535723A5 (enExample) | ||
| JP2020500866A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| BR112015024472A2 (pt) | derivados de quinolina multifuncionais como agentes anti-neurodegenerativos |